Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA1, p42 and p38α

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 7, 2007, Pages 883-892

  Hao, Feng ^a   Tan, Mingqi ^a   Xu, Xuemin ^a   Han, Jiahuai ^b   Miller, Duane D ^c   Tigyi, Gabor ^c   Cui, Mei Zhen ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cell migration; Lysophosphatidic acid; Protein kinases and prostate cancer cells; Receptors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PERTUSSIS TOXIN; SMALL INTERFERING RNA; UO 126;

ARTICLE; CANCER CELL; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYSOPHOSPHOLIPIDS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 14; PERTUSSIS TOXIN; PROSTATIC NEOPLASMS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, SMALL INTERFERING;

MAMMALIA;

EID: 34250004968     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.04.010     Document Type: Article

References (41)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
2. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., and Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31 (2000) 578-583
3. Rubin M.A., Putzi M., Mucci N., Smith D.C., Wojno K., Korenchuk S., and Pienta K.J. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6 (2000) 1038-1045
4. Tantivejkul K., Kalikin L.M., and Pienta K.J. Dynamic process of prostate cancer metastasis to bone. J. Cell. Biochem. 91 (2004) 706-717
5. Loberg R.D., Logothetis C.J., Keller E.T., and Pienta K.J. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J. Clin. Oncol. 23 (2005) 8232-8241
6. Moolenaar W.H. Bioactive lysophospholipids and their G protein-coupled receptors. Exp. Cell Res. 253 (1999) 230-238
7. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev., Cancer 3 (2003) 582-591
8. Tigyi G., and Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J. Biol. Chem. 267 (1992) 21360-21367
9. Tokumura A., Miyake M., Nishioka Y., Yamano S., Aono T., and Fukuzawa K. Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of In vitro fertilization patients. Biol. Reprod. 61 (1999) 195-199
10. Xu Y., Gaudette D.C., Boynton J.D., Frankel A., Fang X.J., Sharma A., Hurteau J., Casey G., Goodbody A., Mellors A., Holub B.J., and Mills G.B. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1 (1995) 1223-1232
11. Siess W., Zangl K.J., Essler M., Bauer M., Brandl R., Corrinth C., Bittman R., Tigyi G., and Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6931-6936
12. Xie Y., Gibbs T.C., Mukhin Y.V., and Meier K.E. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J. Biol. Chem. 277 (2002) 32516-32526
13. Qi C., Park J.H., Gibbs T.C., Shirley D.W., Bradshaw C.D., Ella K.M., and Meier K.E. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J. Cell. Physiol. 174 (1998) 261-272
14. Kue P.F., and Daaka Y. Essential role for G proteins in prostate cancer cell growth and signaling. J. Urol. 164 (2000) 2162-2167
15. Guo C., Luttrell L.M., and Price D.T. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J. Urol. 163 (2000) 1027-1032
16. Gibbs T.C., Xie Y., and Meier K.E. Regulation of expression of EDG family receptors in human prostate cancer cell lines. Ann. N.Y. Acad. Sci. 905 (2000) 290-293
17. Im D.S., Heise C.E., Harding M.A., George S.R., O'Dowd B.F., Theodorescu D., and Lynch K.R. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57 (2000) 753-759
18. Daaka Y. Mitogenic action of LPA in prostate. Biochim. Biophys. Acta 1582 (2002) 265-269
19. Gioeli D., Mandell J.W., Petroni G.R., Frierson Jr. H.F., and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59 (1999) 279-284
20. Price D.T., Rocca G.D., Guo C., Ballo M.S., Schwinn D.A., and Luttrell L.M. Activation of extracellular signal-regulated kinase in human prostate cancer. J. Urol. 162 (1999) 1537-1542
21. Uzgare A.R., Kaplan P.J., and Greenberg N.M. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 55 (2003) 128-139
22. Durgam G.G., Tsukahara R., Makarova N., Walker M.D., Fujiwara Y., Pigg K.R., Baker D.L., Sardar V.M., Parrill A.L., Tigyi G., and Miller D.D. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg. Med. Chem. Lett. 16 (2006) 633-640
23. Huang S., Jiang Y., Li Z., Nishida E., Mathias P., Lin S., Ulevitch R.J., Nemerow G.R., and Han J. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 6 (1997) 739-749
24. Jiang Y., Chen C., Li Z., Guo W., Gegner J.A., Lin S., and Han J. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J. Biol. Chem. 271 (1996) 17920-17926
25. Jiang Y., Gram H., Zhao M., New L., Gu J., Feng L., Di Padova F., Ulevitch R.J., and Han J. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J. Biol. Chem. 272 (1997) 30122-30128
26. Li Z., Jiang Y., Ulevitch R.J., and Han J. The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228 (1996) 334-340
27. Cui M.Z., Zhao G., Winokur A.L., Laag E., Bydash J.R., Penn M.S., Chisolm G.M., and Xu X. Lysophosphatidic acid induction of tissue factor expression in aortic smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 224-230
28. Schaeffer H.J., and Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19 (1999) 2435-2444
29. Ono K., and Han J. The p38 signal transduction pathway: activation and function. Cell. Signal. 12 (2000) 1-13
30. Hwang Y.S., Hodge J.C., Sivapurapu N., and Lindholm P.F. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol. Carcinog. 45 (2006) 518-529
31. Murph M., Tanaka T., Liu S., and Mills G.B. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin. Cancer Res. 12 (2006) 6598-6602
32. Anliker B., and Chun J. Cell surface receptors in lysophospholipid signaling. Semin. Cell Dev. Biol. 15 (2004) 457-465
33. Goetzl E.J., Graeler M., Huang M.C., and Shankar G. Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer. Sci. World J. 2 (2002) 324-338
34. Noguchi K., Ishii S., and Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278 (2003) 25600-25606
35. Lee C.W., Rivera R., Gardell S., Dubin A.E., and Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281 (2006) 23589-23597
36. Kotarsky K., Boketoft A., Bristulf J., Nilsson N.E., Norberg A., Hansson S., Owman C., Sillard R., Leeb-Lundberg L.M., and Olde B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 318 (2006) 619-628
37. Guo R., Kasbohm E.A., Arora P., Sample C.J., Baban B., Sud N., Sivashanmugam P., Moniri N.H., and Daak Y. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147 (2006) 4883-4892
38. Putz T., Culig Z., Eder I.E., Nessler-Menardi C., Bartsch G., Grunicke H., Uberall F., and Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res. 59 (1999) 227-233
39. Frankenberry K.A., Somasundar P., McFadden D.W., and Vona-Davis L.C. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am. J. Surg. 188 (2004) 560-565
40. Wesley U.V., McGroarty M., and Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 65 (2005) 1325-1334
41. Baudhuin L.M., Cristina K.L., Lu J., and Xu Y. Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol. Pharmacol. 62 (2002) 660-671